Get the Stockscreener App
2.63
27.67%
0.57
After Hours:
2.63
Nautilus Biotechnology Inc stock is traded at $2.63, with a volume of 14.62M.
It is up +27.67% in the last 24 hours and up +172.26% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$2.06
Open:
$2.03
24h Volume:
14.62M
Relative Volume:
1.35
Market Cap:
$334.68M
Revenue:
Net Income/Loss:
$-57.09M
P/E Ratio:
-5.8224
EPS:
-0.4517
Net Cash Flow:
$-51.43M
1W Performance:
+21.20%
1M Performance:
+172.26%
6M Performance:
-13.20%
1Y Performance:
+171.13%
1-Day Range:
$1.97
$2.68
1-Week Range:
$1.88
$2.68
52-Week Range:
$0.8411
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.63 | 334.68M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
501.95 | 127.22B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.89 | 90.58B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
782.04 | 80.51B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.61 | 51.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.17 | 41.87B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-26 | Initiated | Roth Capital | Buy |
| Sep-09-26 | Initiated | Leerink Partners | Outperform |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 - GlobeNewswire Inc.
Nautilus Biotechnology Files $300 Million Shelf Registration - Moomoo
NAUT Stock Price, Quote & News - Syfe
NAUT Stock Climbs As Wall Street Backs Voyager Platform - StocksToTrade
NAUT Stock Climbs As Bullish Coverage Backs Voyager Platform - timothysykes.com
Nautilus Biotechnology Inc. (NAUT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nautilus Biotechnology NAUT Draws Bullish Analyst Wave - StocksToTrade
September 2026 Penny Stocks Worth Watching - Simply Wall Street
Roth/MKM initiates Nautilus Biotechnology stock with buy rating - Investing.com
Nautilus Biotechnology Establishes New At-The-Market Offering - The Globe and Mail
Andreessen Horowitz stake in Nautilus (NASDAQ: NAUT) falls below 5% - Stock Titan
Nautilus Biotechnology Establishes New At-The-Market Offering - TipRanks
Nautilus Biotechnology May Offer Up To $300 Million Of SecuritiesSEC Filing - TradingView
Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3% - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) lines up new $300M fundraising capacity - Stock Titan
Nautilus Biotechnology Files $300 Million Shelf Registration - Yahoo Finance
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms - Investing News Network
Nautilus Biotechnology paper on tau proteoform analysis published in Nature Methods - Traders Union
Nautilus found 130 forms of a protein linked to Alzheimer’s. Some appeared in just 0.1% of samples. - Stock Titan
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceWyckoff Accumulation - dars.gov.et
Nautilus Biotechnology heads to HUPO 2026 to unveil Voyager platform breakthroughs - Traders Union
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceFactor Rotation - dars.gov.et
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceRunaway Gap - dars.gov.et
Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesValue Area Low - vinanet.vn
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesCommon Gap - dars.gov.et
Nautilus (NAUT) Financial Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Trading Move - vinanet.vn
Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionOBV Breakout - siam.in
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks
NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn
Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan
Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelLiquidity Order Flow - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsMonthly Profile - careplusvn.com
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsUpthrust Pattern - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsGamma Flip Level - www.dars.gov.et
Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat
Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - kalkine.ca
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat
Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary - tradingview.com
Nautilus Biotechnology Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast - Investing.com
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Mar 04 '26 |
Buy |
2.61 |
25,000 |
65,238 |
10,366,721 |
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
2.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):